logo
Plus   Neg
Share
Email

Argos To Terminate ADAPT Study; Plans To Explore Strategic Alternatives

Argos Therapeutics, Inc. (ARGS) reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastatic renal cell carcinoma. Based on the results, the company has decided to discontinue the trial.

Argos said it plans to explore a wide range of strategic alternatives that may include a potential merger or sale of the company, among other potential alternatives. The company has retained Stifel, Nicolaus & Company, Incorporated to serve as its financial advisor in the process.

Argos also reported that it does not expect to regain compliance with The Nasdaq Capital Market continued listing requirements by the April 24, 2018 deadline. As a result, Argos expects that its common stock will be delisted from The Nasdaq Capital Market and that trading in the company's common stock on The Nasdaq Capital Market will be suspended effective at the open of business on April 23, 2018.

Argos Therapeutics has filed an application to transfer trading and quotation of its common stock to the OTCQB Venture Market, operated by OTC Markets Group Inc., under its current trading symbol, ARGS, effective as of April 23, 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dunkin' Brands Group said it is rolling out the Beyond Sausage Sandwich to more than 9,000 restaurants nationwide, starting November 6. The sandwich features a plant-based sausage patty from alternative meat maker Beyond Meat. Beyond Meat's breakfast sausage patty is made with plant-based protein and a mix of spices crafted specifically for Dunkin'. Boeing said it understands and regrets the concern caused by the publications of instant messages involving a former test pilot that he "unknowingly" lied to regulators about a flight-control system on the Boeing 737 Max aircraft. The aircraft maker said it especially regrets the difficulties that the release of the messages presented for the U.S. Federal Aviation Administration or FAA. Boeing said Sunday that it had informed the Federal Aviation Administration and international regulators on multiple occasions about the expanded role of the flight-control software in 737 MAX, which was linked to two fatal crashes that killed 346 people.
Follow RTT
>